MPI Research

MPI Research has appointed David Serota, Ph.D., DABT to the position of vice president, toxicology and pathology, as well as a member of the company’s senior management team, and Tina Rogers, Ph.D., DABT joined the company as the associate director of research.

Dr. Serota will oversee more than 60 study directors and serve as the senior principal study director on several critical ongoing testing programs. He has more than 31 years of experience and previously served as the director of toxicology at Southern Research Institute and as director of laboratory operations at Hazleton Laboratories Vienna (now Covance). Most recently, Dr. Serota was the executive director of toxicology and senior study director at MPI Research.

“Dr. Serota’s experience and innovation have set a performance precedent at MPI Research. He has played a key role in our capacity expansion projects, which have allowed us to provide our sponsors with the timely study starts they need to keep their projects moving forward. In fact, our Sponsors often actively seek his expertise,” said Jim Laveglia, Ph.D., executive vice president and director of research at MPI Research. “With Dr. Serota leading our toxicology and pathology efforts, our Sponsors can look forward to continued service enhancements and operational excellence.”

In her new role, Dr. Rogers will lead initiatives to enhance the targeted discovery research offerings at the company, focusing on biotherapeutics, including viral and other gene vectors as well as cell therapy. She will also concentrate on advancing specialized services and capabilities in other key areas of the company. She has more than 15 years of experience in the CRO industry and has held key leadership positions, including vice president of drug development at Southern Research Institute.

“Dr. Rogers is a knowledgeable leader with proven business acumen,” said Dr. Laveglia. “Her unique combination of credentials and experience will only further strengthen our research team and efforts to provide Sponsors with timely, top-quality, and cost-effective preclinical drug development services.”